<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38456188</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-5723</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Gastro hep advances</Title><ISOAbbreviation>Gastro Hep Adv</ISOAbbreviation></Journal><ArticleTitle>Factors That Predict Magnitude, Timing, and Persistence of Placebo-Like Response in Patients With Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>229</EndPage><MedlinePgn>221-229</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastha.2023.10.003</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Placebo response impedes the development of novel irritable bowel syndrome (IBS) therapies and the interpretability of randomized clinical trials. This study sought to characterize the magnitude, timing, and durability of IBS symptom relief in patients undergoing a non-drug placebo-like control.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred forty-five Rome III-diagnosed patients (80% F, M age = 42 years) were assigned to education/nondirective support delivered over a 10-week acute phase. Treatment response was based on the IBS version of the Clinical Global Improvement Scale completed 2 weeks after treatment ended. Candidate predictors were assessed at baseline (eg, emotion regulation, pain catastrophizing, distress, neuroticism, stress, somatization, gastrointestinal-specific anxiety) or clinically relevant points during treatment (patient-provider relationship, treatment expectancy/credibility).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Midtreatment response was associated with lower levels of stress and somatization at baseline and greater patient-provider agreement on treatment tasks (<i>P</i> &lt; .001). Treatment response was associated with baseline gastroenterologist-rated IBS severity, anxiety, ability to reappraise emotions to reduce their impact [cognitive reappraisal], and agreement that provider and patient shared goals from provider perspective (<i>P</i> &lt; .001). The day-to-day ability to reappraise emotions at baseline distinguished rapid from delayed placebo responders (<i>P</i> = .011).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patient beliefs (eg, perceived stress, cognitive reappraisal) impacted the magnitude, timing, and persistence of placebo response measured at midway point of acute phase and 2 weeks after treatment discontinuation. Baseline beliefs that patients could alter the impact of stressful events by rethinking their unpleasantness distinguished rapid vs delayed placebo responders. Collaborative agreement between doctor and patient around shared tasks/goals from the clinician perspective predicted placebo response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lackner</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Brian M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zilcha-Mano</LastName><ForeName>Sigal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Haifa, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radziwon</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krasner</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudleski</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Division of Behavioral Medicine, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enck</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine VI (Psychosomatic Medicine and Psychotherapy), University Hospital T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK096606</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128927</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK077738</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Gastro Hep Adv</MedlineTA><NlmUniqueID>9918350485906676</NlmUniqueID><ISSNLinking>2772-5723</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emotion Regulation</Keyword><Keyword MajorTopicYN="N">Expectancies</Keyword><Keyword MajorTopicYN="N">Placebo Effect</Keyword><Keyword MajorTopicYN="N">Randomized Clinical Trials</Keyword></KeywordList><CoiStatement>Conflicts of Interest: The authors disclose no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>8</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38456188</ArticleId><ArticleId IdType="mid">NIHMS1970002</ArticleId><ArticleId IdType="pmc">PMC10919349</ArticleId><ArticleId IdType="doi">10.1016/j.gastha.2023.10.003</ArticleId><ArticleId IdType="pii">S2772-5723(23)00162-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Staudacher H.M., Black C.J., Teasdale S.B., et al. Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023;20:582&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10237074</ArticleId><ArticleId IdType="pubmed">37268741</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Lacy B.E., Talley N.J. Irritable bowel syndrome. N&#xa0;Engl J Med. 2017;376(26):2566&#x2013;2578.</Citation><ArticleIdList><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C.J., Ford A.C. Best management of irritable bowel syndrome. Frontline Gastroenterol. 2021;12(4):303&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8231425</ArticleId><ArticleId IdType="pubmed">34249316</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M., Chang L. Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles. Gastroenterology. 2008;135(6):1877&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671226</ArticleId><ArticleId IdType="pubmed">18848833</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Aziz Q., Barbara G., et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A.C., Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010;32(2):144&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">20412064</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanigasekera V., Wartolowska K., Huggins J.P., et al. Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging. Br J Anaesth. 2018;120(2):299&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">29406179</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee J., Sugarman M.A., Ballou S., et al. Placebo response in chronic idiopathic constipation: a systematic review and meta-analysis. Am J Gastroenterol. 2019;114(12):1838&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">31592782</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S.M., Stason W.B., Legedza A., et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005;17(3):332&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916620</ArticleId></ArticleIdList></Reference><Reference><Citation>Welge J.A., Keck P.E. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology. 2003;166(1):1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">12494247</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Klosterhalfen S., Weimer K., et al. The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1889&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130397</ArticleId><ArticleId IdType="pubmed">21576146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaptchuk T.J., Hemond C.C., Miller F.G. Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ. 2020;370:m1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">32690477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesser H., Hedman-Lagerl&#xf6;f E., Andersson E., et al. How does exposure therapy work? A comparison between generic and gastrointestinal anxiety-specific mediators in a dismantling study of exposure therapy for irritable bowel syndrome. J&#xa0;Consult Clin Psychol. 2018;86(3):254&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">29504793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Jaccard J. Specific and common mediators of gastrointestinal symptom improvement in patients undergoing education/support vs. cognitive behavioral therapy for irritable bowel syndrome. J&#xa0;Consult Clin Psychol. 2021;89(5):435&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380705</ArticleId><ArticleId IdType="pubmed">34124927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch I. Response expectancy as a determinant of experience and behavior. Am Psychol. 1985;40(11):1189.</Citation></Reference><Reference><Citation>Kirsch I. Response expectancy and the placebo effect. Int Rev Neurobiol. 2018;138:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29681336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch I., Harrington A. Harvard Univ. Press; Cambridge, MA: 1997. The placebo effect: an interdisciplinary exploration.</Citation></Reference><Reference><Citation>Ashar Y.K., Chang L.J., Wager T.D. Brain mechanisms of the placebo effect: an affective appraisal account. Annu Rev Clin Psychol. 2017;13:73&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28375723</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A. 2012 David Sun lecture: helping your patient by helping yourself--how to improve the patient-physician relationship by optimizing communication skills. Am J Gastroenterol. 2013;108(4):521&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511457</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielmans G.I., Pasek L.F., McFall J.P. What are the active ingredients in cognitive and behavioral psychotherapy for anxious and depressed children? A meta-analytic review. Clin Psychol Rev. 2007;27(5):642&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Gudleski G.D., Keefer L., et al. Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8(5):426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144205</ArticleId><ArticleId IdType="pubmed">20170751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S., Beath A., Kaptchuk T.J., et al. Factors associated with response to placebo in patients with irritable bowel syndrome and constipation. Clin Gastroenterol Hepatol. 2018;16(11):1738&#x2013;1744.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414074</ArticleId><ArticleId IdType="pubmed">29654913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chey W.D., Lembo A.J., Rosenbaum D.P. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017;112(5):763&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5418559</ArticleId><ArticleId IdType="pubmed">28244495</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman D.A., Corazziari E., Talley N.J., et al. 2nd ed. Degnon Associates; McLean, VA: 2006. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus.</Citation></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Keefer L., Jaccard J., et al. The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome. Contemp Clin Trials. 2012;33(6):1293&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468694</ArticleId><ArticleId IdType="pubmed">22846389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Jaccard J., Keefer L., et al. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018;155(1):47&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035059</ArticleId><ArticleId IdType="pubmed">29702118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringstr&#xf6;m G., St&#xf6;rsrud S., Posserud I., et al. Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. Eur J Gastroenterol Hepatol. 2010;22(4):420&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">19923998</ArticleId></ArticleIdList></Reference><Reference><Citation>Labus J., Gupta A., Gill H.K., et al. Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. Aliment Pharmacol Ther. 2013;37(3):304&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829380</ArticleId><ArticleId IdType="pubmed">23205588</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedland K.E., Mohr D.C., Davidson K.W., et al. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med. 2011;73(4):323&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091006</ArticleId><ArticleId IdType="pubmed">21536837</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine E.J., Whitehead W.E., Chey W.D., et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1538&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678567</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk D.C., Dworkin R.H., Allen R.R., et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">14659516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Jaccard J., Krasner S.S., et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6(8):899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2630498</ArticleId><ArticleId IdType="pubmed">18524691</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein K.B. In: Approach to the patient with chronic gastrointestinal disorders. Corazziari E., editor. Messaggi; Milan: 1999. Assessment of treatment outcome in the functional gastrointestinal disorders.</Citation></Reference><Reference><Citation>Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen M.P., Keefe F.J., Lefebvre J.C., et al. One- and two-item measures of pain beliefs and coping strategies. Pain. 2003;104(3):453&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927618</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger C.D. Mind Garden; Palo Alto, CA: 1983. Manual for the State-Trait Inventory STAI (Form Y)</Citation></Reference><Reference><Citation>Meyer T.J., Miller M.L., Metzger R.L., et al. Development and validation of the penn state worry questionnaire. Behav Res Ther. 1990;28(6):487&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">2076086</ArticleId></ArticleIdList></Reference><Reference><Citation>Derogatis L.R. NCS Pearson, Incorporated; Minneapolis, MN: 2001. BSI 18, brief symptom inventory 18: administration, scoring and procedures manual.</Citation></Reference><Reference><Citation>Cohen S., Kamarck T., Mermelstein R. A&#xa0;global measure of perceived stress. J&#xa0;Health Soc Behav. 1983;24(4):385&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">6668417</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross J.J., John O.P. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. J&#xa0;Pers Soc Psychol. 2003;85(2):348&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">12916575</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J., Holroyd K. University at Buffalo, SUNY; Buffalo: 2004. Locus of control scale-IBS version (a self report measure for assessing perceived control in IBS patients)</Citation></Reference><Reference><Citation>Lackner J., Krasner S., Holroyd K. University at Buffalo, SUNY; Buffalo: 2004. IBS management self efficacy scale.</Citation></Reference><Reference><Citation>Devilly G.J., Borkovec T.D. Psychometric properties of the credibility/expectancy questionnaire. J&#xa0;Behav Ther Exp Psychiatry. 2000;31(2):73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">11132119</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher R.L., Gillaspy J.A. Development and validation of a revised short version of the working alliance inventory. Psychother Res. 2006;16(1):12&#x2013;25.</Citation></Reference><Reference><Citation>van der Meulen M., Kamping S., Anton F. The role of cognitive reappraisal in placebo analgesia: an fMRI study. Soc Cogn Affect Neurosci. 2017;12(7):1128&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490670</ArticleId><ArticleId IdType="pubmed">28338955</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross J.J. The emerging field of emotion regulation: an integrative review. Rev Gen Psychol. 1998;2(3):271&#x2013;299.</Citation></Reference><Reference><Citation>Wager T.D. The neural bases of placebo effects in pain. Curr Dir Psychol Sci. 2005;14(4):175&#x2013;179.</Citation></Reference><Reference><Citation>Halpert A., Godena E. Irritable bowel syndrome patients' perspectives on their relationships with healthcare providers. Scand J Gastroenterol. 2011;46(7-8):823&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">21561228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hojat M., Louis D.Z., Markham F.W., et al. Physicians' empathy and clinical outcomes for diabetic patients. Acad Med. 2011;86(3):359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">21248604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogle J., Bushnell J.A., Caputi P. Empathy is related to clinical competence in medical care. Med Educ. 2013;47(8):824&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">23837429</ArticleId></ArticleIdList></Reference><Reference><Citation>West C.P., Huschka M.M., Novotny P.J., et al. Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. JAMA. 2006;296(9):1071&#x2013;1078.</Citation><ArticleIdList><ArticleId IdType="pubmed">16954486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenschurz-Schmidt D., Vase L., Scott W., et al. Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pubmed">37230508</ArticleId></ArticleIdList></Reference><Reference><Citation>Brent D.A., Holder D., Kolko D., et al. A&#xa0;clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997;54(9):877&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">9294380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohenschurz-Schmidt D., Draper-Rodi J., Vase L., et al. Blinding and sham control methods in trials of physical, psychological, and self-management interventions for pain (article I): a systematic review and description of methods. Pain. 2023;164(3):469&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9916059</ArticleId><ArticleId IdType="pubmed">36265391</ArticleId></ArticleIdList></Reference><Reference><Citation>Hr&#xf3;bjartsson A., Miller F. Randomized clinical trials of nonpharmacologic treatments. Pain. 2011;164(3)</Citation></Reference><Reference><Citation>Evers A.W.M., Colloca L., Blease C., et al. Implications of placebo and Nocebo effects for clinical practice: expert consensus. Psychother Psychosom. 2018;87(4):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191882</ArticleId><ArticleId IdType="pubmed">29895014</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney C.W., Von Korff M. Regression to the mean in treated versus untreated chronic pain. Pain. 1992;50(3):281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">1280801</ArticleId></ArticleIdList></Reference><Reference><Citation>Agr&#xe9;us L., Sv&#xe4;rdsudd K., Nyr&#xe9;n O., et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109(3):671&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">7657095</ArticleId></ArticleIdList></Reference><Reference><Citation>Talley N.J., Zinsmeister A.R., Van Dyke C., et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pubmed">1889716</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner J.M., Jaccard J., Radziwon C.D., et al. Durability and decay of treatment benefit of cognitive behavioral therapy for irritable bowel syndrome: 12-month follow-up. Am J Gastroenterol. 2019;114(2):330&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6737527</ArticleId><ArticleId IdType="pubmed">30429592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurlander J.E., Chey W.D., Morris C.B., et al. Development and validation of the Patient-Physician Relationship Scale among patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(10):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28544094</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb C.A., DeRubeis R.J., Amsterdam J.D., et al. Two aspects of the therapeutic alliance: differential relations with depressive symptom change. J&#xa0;Consult Clin Psychol. 2011;79(3):279&#x2013;283. Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124012</ArticleId><ArticleId IdType="pubmed">21480694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>